

Haematologica  
HAEMATOL/2015/140558  
Version 2

Response to Comment on Incidence and Risk Factors of  
Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic  
Leukemia Treated with Ibrutinib

Andrew H. Lipsky, Jay N. Lozier, and Andrian Wiestner

Disclosures: Conflict of interest: AW received research funding from Pharmacyclics Inc. All other authors declare no competing interests. Funding: This work was supported by the Intramural Research Program of NHLBI. Pharmacyclics provided ibrutinib and research support.

Contributions: Authors' contributions: AHL, JNL, and AW wrote the paper. AHL analyzed the data and generated figures.